A collaborative team led by a Northeastern University professor may have altered the way we look at drug development for HIV by uncovering some unusual properties of a human protein called APOBEC3G (A3G).
I first became interested in drugs to treat brain diseases with I was a pharmacy student at Northeastern in the early 1980s. After I got my PhD in medicinal chemistry at the University of California–San Francisco, I returned to Boston for a post-doctoral fellowship at Harvard Medical School. At the time, I was drawn to research on neurodegenerative diseases, such as Parkinson’s. But by 1987, I switched to neuropsychiatric diseases, and that’s what I’ve been focused on ever since.